Intrapleural Bevacizumab and Cisplatin Therapy for Malignant Pleural Effusion Caused by Non-small Cell Lung Cancer

Sponsor
Chinese PLA General Hospital
Study ID
NCT01661790
Phase
PHASE3
Status
Completed

Conditions

  • Malignant Pleural Effusion

Eligibility Criteria

Sex
ALL
Age
18 Years - 85 Years
Healthy Volunteers
Not accepted

Interventions

  • Bevacizumab — DRUG
    Bevacizumab300mg\&Cispltin30mg by intrapleural administration of each 2 week
  • Cisplatin — DRUG
    Cisplatin 30mg,intrapleural administration,each 2 week

Study Details

To determine the efficacy and Safety of intrapleural Bevacizumab and cisplatin as a treatment for malignant pleural effusions (MPE) in patients with non-small cell lung cancer (NSCLC).

Key Dates

First listed
Aug 10, 2012
Start date
Aug 31, 2009
Status verified
Mar 2015
Primary completion
Jun 30, 2012
Completion
Oct 31, 2012

Study Design

Enrollment
72 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Bevacizumab & Cisplatin
    Bevacizumab 300mg plus Cisplatin 30mg by intrapleural given every two weeks
  • Active Comparator: Cisplatin
    Cisplatin 30mg by intrapleural given every two weeks

Primary Outcome Measure

Number of Participants With "Complete Response" and "Partial Response" [ Time Frame: from randomization, This treatment was given every two weeks,responses were made by biweekly ]

Related Studies